Twist Bioscience Corporation (TWST) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St to open higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Twist Bioscience Corporation (TWST) to Acquire Abveris
November 22, 2021 7:30 AM ESTTwist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it entered into a definitive agreement to acquire Abveris, (formally known as AbX Biologics, Inc.) a privately held in vivo antibody discovery services company developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global biopharma leaders.
Abveris offers comprehensive antibody discovery and characterization services using its proprietary DiversimAb family of hyperimmune mouse models, the output of which can be humanized using the Twist antibody... More
